MREO vs. ERAS, RANI, TERN, HROW, NATR, ADCT, AMRN, ANRO, PGEN, and ATAI Should you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Erasca (ERAS), Rani Therapeutics (RANI), Terns Pharmaceuticals (TERN), Harrow (HROW), Nature's Sunshine Products (NATR), ADC Therapeutics (ADCT), Amarin (AMRN), Alto Neuroscience (ANRO), Precigen (PGEN), and Atai Life Sciences (ATAI). These companies are all part of the "pharmaceutical preparations" industry.
Erasca (NASDAQ:ERAS ) and Mereo BioPharma Group (NASDAQ:MREO ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.
Erasca has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Mereo BioPharma Group has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500.
Mereo BioPharma Group has higher revenue and earnings than Erasca.
Erasca's return on equity of 0.00% beat Mereo BioPharma Group's return on equity.
Mereo BioPharma Group received 17 more outperform votes than Erasca when rated by MarketBeat users. Likewise, 72.34% of users gave Mereo BioPharma Group an outperform vote while only 62.96% of users gave Erasca an outperform vote.
In the previous week, Mereo BioPharma Group had 10 more articles in the media than Erasca. MarketBeat recorded 19 mentions for Mereo BioPharma Group and 9 mentions for Erasca. Erasca's average media sentiment score of 0.48 beat Mereo BioPharma Group's score of 0.18 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.
67.8% of Erasca shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 21.5% of Erasca shares are held by company insiders. Comparatively, 4.1% of Mereo BioPharma Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Erasca currently has a consensus price target of $7.33, suggesting a potential upside of 237.94%. Mereo BioPharma Group has a consensus price target of $6.50, suggesting a potential upside of 95.20%. Given Mereo BioPharma Group's higher probable upside, equities research analysts plainly believe Erasca is more favorable than Mereo BioPharma Group.
Summary Mereo BioPharma Group beats Erasca on 9 of the 14 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Mereo BioPharma Group Competitors List
Related Companies and Tools
